Literature DB >> 1540238

Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung.

D M Wypij1, J S Nichols, P J Novak, D L Stacy, J Berman, J S Wiseman.   

Abstract

Previous studies of endothelin-1 (ET) synthesis have shown that some cultured endothelial cells secrete an intermediate product, big-endothelin-1 (bigET), suggesting that the processing of secreted bigET to ET may be physiologically significant. In this study, two pertinent ET converting enzyme activities, mast cell chymase I (EC 3.4.21.39) and a phosphoramidon-sensitive, neutral metalloprotease, were identified in a rat lung particulate fraction. We perfused rat lungs with bigET and chymostatin or phosphoramidon to study the relevance of these two proteases to the processing of extracellular bigET in vivo. Addition of compound 48/80 (a compound which activates mast cells, causing degranulation and release of chymase) to the perfusion buffer greatly increased hydrolysis of exogenously added bigET to ET. ET formation was inhibited completely by 32 microM chymostatin, whereas inhibition by 50 microM phosphoramidon was incomplete and variable. Perfusate histamine levels were used to monitor the extent of mast cell degranulation, and inhibition of ET production by phosphoramidon was attributed to inhibition of degranulation, per se. There was a direct correlation between perfusate ET and histamine levels in both control and phosphoramidon-treated (but not chymostatin-treated) lungs. Our results suggest that chymase from lung mast cells is capable of physiologically relevant extracellular processing by bigET to ET in the perfused rat lung.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540238     DOI: 10.1016/0006-2952(92)90252-e

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  20 in total

Review 1.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  The role of endothelin receptor antagonists in the treatment of chronic heart failure.

Authors:  W Kiowski; G Sütsch
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

3.  Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice.

Authors:  H Ju; R Gros; X You; S Tsang; M Husain; M Rabinovitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 4.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 5.  Endothelin Signaling in Bone.

Authors:  Jasmin Kristianto; Michael G Johnson; Rafia Afzal; Robert D Blank
Journal:  Endocrinol Metab Clin North Am       Date:  2016-11-26       Impact factor: 4.741

6.  Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice.

Authors:  Naotaka Shiota; Eiichi Kakizoe; Keiko Shimoura; Tetsuya Tanaka; Hideki Okunishi
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

7.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats.

Authors:  C Guo; H Ju; D Leung; H Massaeli; M Shi; M Rabinovitch
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

8.  Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11.

Authors:  Z A Abassi; E Golomb; R Bridenbaugh; H R Keiser
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1.

Authors:  Martin Houde; Marc-David Jamain; Julie Labonté; Louisane Desbiens; Gunnar Pejler; Michael Gurish; Shinji Takai; Pedro D'Orléans-Juste
Journal:  J Pharmacol Exp Ther       Date:  2013-04-17       Impact factor: 4.030

Review 10.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.